Date of Document: September 25, 2021

CURRICULUM VITAE

Kenneth D. Friedman MD

Professor Department of Medicine Division of and Oncology - Medicine

OFFICE ADDRESS: Clinical Center 9200 W Wisconsin Ave Milwaukee, WI 53226 Phone: 414-805-4600

EDUCATION: 09/1972 - 05/1976 BS, Cornell University, Ithaca, NY 09/1976 - 06/1980 MD, SUNY Upstate Medical center, Syracuse, NY

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: 07/01/1980 - 06/30/1983 Resident, Internal Medicine, Temple University Hospital, 1901 Broad Street, Philadelphia, PA 07/01/1983 - 06/30/1986 Fellow, Internal Medicine, Hematology/medical Oncology, Columbia Presbyterian Medical Center, 638 West 168th Street, New York, NY 10036 07/01/1986 - 07/30/1989 Fellow, Transfusion Medicine, BloodCenter of Wisconsin, 638 North 18th Street, PO Box 2178, 638 North 18th Street, Milwaukee, WI 53217-2178

FACULTY APPOINTMENTS: 08/01/1989 - Present Associate Professor, Internal Medicine and Pathology, Medical College of Wisconsin, 9200 West Wisconsin Ave, Milwaukee, WI 53226 08/01/1989 - 06/30/1995 Assistant Professor, Internal Medicine and Pathology, University of New Mexico, 915 Camino de Salud, Albuquerque, NM 87131 07/01/1995 - 07/31/1997 Associate Professor, Internal Medicine and Pathology, University of New Mexico, 915 Camino de Salud, Albuquerque, NM 87131

ADMINISTRATIVE APPOINTMENTS: 08/01/1989 - 08/31/1995 Associate Medical Director, United Blood Services -New Mexico, Albuquerque, NM 87131 08/1989 - 07/1997 Associate Medical Director, Ted R Montoya Hemophilia Program, Lomas NE, Albuquerque, NM 87131 09/01/1995 - 07/31/1997 Medical Director, United Blood Services -New Mexico, Albuquerque, NM 87131 08/01/1997 - Present Medical Director, Hemostasis Reference Laboratory, BloodCenter of Wisconsin, 638 North 18th Street, PO Box 2178, 638 North 18th Street, Milwaukee, WI 53217-2178 08/01/1997 - Present Associate Medical Director, Comprehensive Center for Disorders, BloodCenter of Wisconsin, 8725 Watertown Plank Road, Milwaukee, WI 53226 01/01/2000 - 08/31/2004 Co-Medical Director, Transfusion Service, Aurora Health Care, Oklahoma Ave, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

Board Certified Issue Date Expiration Internal Medicine 1983 None Medical Oncology 1985 None

1 / 7 Hematology 1986 None Transfusion Medicine None

Licensure Number Issue Date Expiration MD027271E 07/1982 1984 155406 06/1983 12/1998 27624 07/1986 10/2013 89-196 08/1989 07/2014

AWARDS AND HONORS: 1975 - Present Tau Beta Pi - Engineering Honor Society 1979 - Present Alpha Omega Alpha 1993 - 1994 Apple for the teacher Award, School of Medicine, University of New Mexico

BIBLIOGRAPHY Refereed Journal Publications/Original Papers 1. Kruskall MS, Bodner MS, Dzik WH, Friedman KD, Gerber L, Gould SA, Gravlee G, Schoenleber DG, Yomtovian R. An annotated bibliography on autologous transfusion. Transfusion. 1992 Mar- Apr;32(3):286-90. 2. Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for 91 in in a variant form of . J Biol Chem. 1991 Oct 15;266(29):19146-9. 3. Friedman KD, Rosen NL, Newman PJ, Montgomery RR. Enzymatic amplification of specific cDNA inserts from lambda gt11 libraries. Nucleic Acids Res. 1988 Sep 12;16(17):8718. PMCID: PMC338596 4. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. J Clin Invest. 1987 Jun;79(6):1642-7. PMCID: PMC424490 5. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient activity. Blood. 1988 Aug;72(2):616-20. 6. Tollefson DF, Friedman KD, Marlar RA, Bandyk DF, Towne JB. deficiency. A cause of unusual or unexplained . Arch Surg. 1988 Jul;123(7):881-4. 7. Friedman KD, Borok Z, Owen J. cofactor activity and III antigen levels in preeclampsia. Thromb Res. 1986 Aug 15;43(4):409-16. 8. Goodnough LT, Price TH, Parvin CA, Friedman KD, Vogler WR, Khan N, Sacher R, Johnston M, Wissel M, Ciavarella D. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol. 1994 Aug;87(4):695-9. 9. Kruskall MS, Yomtovian R, Dzik WH, Friedman KD, Umlas J. On improving the cost-effectiveness of autologous blood transfusion practices. Transfusion. 1994 Mar;34(3):259-64. 10. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion. 1994 Jan;34(1):66-71. 11. Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously. Clin Cancer Res. 1995 Oct;1(10):1145-52. 12. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of , factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost. 1999 May;81(5):733-8. 13. Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD. Contribution of the Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. Br J Haematol. 1999 Jul;106(1):237-9. 14. Dinauer DM, Friedman KD, Hessner MJ. Allelic distribution of the glycoprotein Ia (alpha2-integrin)

2 / 7 C807T/G873A dimorphisms among caucasian patients and six racial groups. Br J Haematol. 1999 Dec;107(3):563-5. 15. Hessner MJ, Budish MA, Friedman KD. Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes. Clin Chem. 2000 Aug;46(8 Pt 1):1051-6. 16. Ledford M, Friedman KD, Hessner MJ, Moehlenkamp C, Williams TM, Larson RS. A multi-site study for detection of the factor V (Leiden) from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay. J Mol Diagn. 2000 May;2(2):97-104. PMCID: PMC1906901 17. Hessner MJ, Friedman KD, Voelkerding KV, Huber S, Ryan D, Nuccie B, Ledford M. Multisite study for genotyping of the factor II (prothrombin) G20210A mutation by the invader assay. Clin Chem. 2001 Nov;47(11):2048-50. 18. Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ. Anti-GPVI-associated ITP: an acquired disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004 Sep 01;104(5):1350-5. 19. Raife T, Friedman KD, Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost. 2004 Aug;92(2):387-93. 20. Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost. 2004 Sep;2(9):1601-9. 21. Cooley BC, Chen CY, Friedman KD, Datta Y. A prothrombotic phenotype in the Copenhagen rat strain. Thromb Res. 2005;115(1-2):153-7. 22. Kakela JK, Friedman KD, Haberichter SL, Buchholz NP, Christopherson PA, Kroner PA, Gill JC, Montgomery RR, Bellissimo DB. Genetic in von Willebrand disease identified by DHPLC and DNA sequence analysis. Mol Genet Metab. 2006 Mar;87(3):262-71. 23. Raife TJ, Friedman KD, Dwyre DM. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic : reconsideration of treatment with cryopoor plasma. Transfusion. 2006 Jan;46(1):74-9. 24. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of with prothrombin complex concentrate. J Thromb Haemost. 2006 May;4(5):967-70. 25. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion. 2007 Jan;47(1):120-5. 26. Slayton WB, Patel M, Sola-Visner M, Harris N, Rivers A, Montgomery RR, Friedman KD. Type 2B von Willebrand disease associated with the release of platelet agglutinates from in the bone marrow. J Pediatr Hematol Oncol. 2008 Sep;30(9):708-11. PMCID: PMC5592795 27. Dwyre DM, Dursteler B, Nashelsky M, Friedman KD, Raife TJ. Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic . J Clin Apher. 2009;24(3):106-10. 28. Erickson YO, Samia NI, Bedell B, Friedman KD, Atkinson BS, Raife TJ. Elevated procalcitonin and C- reactive protein as potential biomarkers of in a subpopulation of thrombotic microangiopathy patients. J Clin Apher. 2009;24(4):150-4. PMCID: PMC2750870 29. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost. 2009 Nov;7(11):1832-9. PMCID: PMC3825106 30. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010 Jul 15;116(2):280-6. PMCID: PMC2910611 31. Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RR. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010 Jun;8(6):1431-3. PMCID: PMC3892206 32. Lee CA, Hubbard A, Sabin CA, Budde U, Castaman G, Favaloro EJ, Friedman KD, Federici AB, I5th-SSC Subcommittee on VWF. Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. J Thromb Haemost. 2011 Jan;9(1):220-2. 33. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG,

3 / 7 Montgomery RR. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011 Feb 10;117(6):e67-74. PMCID: PMC3056647 34. Gupta M, Lillicrap D, Stain AM, Friedman KD, Carcao MD. Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease. Pediatr Blood Cancer. 2011 Dec 01;57(6):1081-3. 35. Samia NI, Friedman KD, Gottschall JL, Raife TJ. Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy. J Clin Apher. 2011;26(3):138-45. 36. Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost. 2011 Jul;37(5):528-34. PMCID: PMC3807766 37. Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012 Mar 01;119(9):2135-40. PMCID: PMC3311248 38. Cushing M, Kawaguchi K, Friedman KD, Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012 Jul;52(7):1535-41. 39. Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012 May 10;119(19):4543-53. PMCID: PMC3362367 40. Raife TJ, Friedman, KD. Therapeutic use of Blood Components. In: Rakel RE Bope ET, eds. Conn’s Current Concepts 2002 Philadelphia: WB Saunders Company 2002;450-460.

Books, Chapters, and Reviews 1. Friedman KD, Rosen NL, Newman PJ, Montgomery RR. Screening of lambda gt111 libraries. In: Innis M, Gelland D, Sninsky J, White T, eds. PCR Protocols: A Guide to Methods and Applications. Orlando: Academic Press, 1990:253 258. 2. Stehling LC, Dzik WH, Friedman KD, Gerber L, Gould S, Kleinman S, Kruskall M, Popovsky MA, Schoenleber DG, Yomtovian R. Guidelines for blood salvage and reinfusion in surgery and trauma. Arlington, VA: American Association of Blood Banks, 1990. 3. Friedman KD (moderator): Autologous transfusion programs: Discussion 1 in Stehling LC (Editor): Perioperative Autologous Transfusion. Arlington, VA: American Association of Blood Banks, 1991:57 66. 4. Friedman KD, Menitove JE: Preparation and clinical use of plasma and plasma fractions. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ. Williams Hematology. New York 2000 5. Friedman, KD, Raife TJ. Management of clotting disorder/ in the dying patient. In: Berger AM, Portenoy RK, Weissman DE, eds. Principles and Practice of Palliative Care and Supportive Oncology Philadelphia: Lippincott Williams & Wilkins 2002;452-462. 6. Raife TJ, Friedman, KD. Therapeutic use of Blood Components. In: Rakel RE Bope ET, eds. Conn’s Current Concepts 2002 Philadelphia: WB Saunders Company 2002;450-460. 7. Friedman KD, Rodgers GM: Inherited disorders. In: Lee RG, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe’s Clinical Hematology Baltimore: Williams and Wilkins, 2003. 8. Friedman, KD, Raife TJ. Management of hypercoagulable states and . In: Berger AM, Portenoy RK, Weissman DE, eds. Principles and Practice of Palliative Care and Supportive Oncology Philadelphia: Lippincott Williams & Wilkins; 2006; 347-355. 2007. 9. Friedman, KD. Hemostatic Disorders. In King KE, Bandarenko N, Campbell-Lee SA, Cooling LW, Cushing MM, Friedman KD, Pomper G, Gottschall JL, eds. Blood Transfusion Therapy: A Physician’s Handbook. Bethesda MD. AABB 2011; 101-144. 10. Petkova JH, Raife TJ, Friedman, KD. Management of hypercoagulable states and coagulopathy. In: Berger AM, Shuster JL, Van Roenn JH, eds. Principles and Practice of Palliative Care and Supportive Oncology Philadelphia: Lippincott Williams & Wilkins 2013;430-441. 11. Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012 Jul;10(7):1417-24. PMCID: PMC3809952 12. Flood VH, Gill JC, Christopherson PA, Wren JS, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Comparison of type I, type III and type VI collagen binding assays in diagnosis of

4 / 7 von Willebrand disease. J Thromb Haemost. 2012 Jul;10(7):1425-32. PMCID: PMC3809762 13. Dumont LJ, Cancelas JA, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukoreduced apheresis stored in a new platelet additive solution. Transfusion. 2013 May;53(5):972-80. 14. Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH. Use of purified concentrate for and importance of laboratory fibrinogen activity measurement. Pediatr Blood Cancer. 2013 Mar;60(3):500-2. PMCID: PMC4461026 15. Flood VH, Gill JC, Friedman KD, Christopherson PA, Jacobi PM, Hoffmann RG, Montgomery RR, Haberichter SL, Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem. 2013 Apr;59(4):684-91. PMCID: PMC3852672 16. Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood. 2013 May 02;121(18):3742-4. PMCID: PMC3643771 17. Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, Friedman KD, Sadler JE. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013 Aug;11(8):1511-8. PMCID: PMC3807872 18. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014 Jun;111(6):1133-40. 19. Francis JC, Hui SK, Mahoney D Jr, Dietrich JE, Friedman KD, Soundar E, Srivaths LV. Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H. . 2014 May;20(3):e211-4. 20. Allan JN, Friedman KD, DeSancho MT. Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N. Int J Hematol. 2014 Dec;100(6):602-6. 21. Costello JP, Diab YA, Philippe-Auguste M, Jones MB, Shankar V, Friedman KD, Nath DS. Acquired von Willebrand syndrome in a child following Berlin Heart EXCOR Pediatric Ventricular Assist Device implantation: case report and concise literature review. World J Pediatr Congenit Heart Surg. 2014 Oct;5(4):592-8. 22. Gosselin RC, Adcock Funk DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, Moll S. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med. 2014 Dec;138(12):1680-4. 23. Muia J, Zhu J, Gupta G, Haberichter SL, Friedman KD, Feys HB, Deforche L, Vanhoorelbeke K, Westfield LA, Roth R, Tolia NH, Heuser JE, Sadler JE. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18584-9. PMCID: PMC4284596 24. Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR, Zimmerman Program Investigators. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015 Apr 02;125(14):2297-304. PMCID: PMC4383803 25. Hillarp A, Friedman KD, Adcock-Funk D, Tiefenbacher S, Nichols WL, Chen D, Stadler M, Schwartz BA. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method. Haemophilia. 2015 Nov;21(6):837-45. 26. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016 Feb;14(2):248-61. 27. Kitchen S, Blakemore J, Friedman KD, Hart DP, Ko RH, Perry D, Platton S, Tan-Castillo D, Young G, Luddington RJ. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. J Thromb Haemost. 2016 Apr;14(4):757-64. 28. Epperla N, Hemauer K, Friedman KD, George JN, Foy P. Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol. 2016 06;91(6):644-6. 29. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD,

5 / 7 Lillicrap D, Peake IR, Montgomery RR. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016 05 19;127(20):2481-8. PMCID: PMC4874228 30. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol. 2016 06;91(6):E313-4. 31. Abbott DW, Friedman KD, Karafin MS. Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findings. Transfus Apher Sci. 2016 Dec;55(3):318-322. 32. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H, International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 02;15(2):312-322. 33. Bercovitz RS, Drew CS, Bushee CL, Popovsky MA, Friedman KD, Anani WQ. A microfluidic analysis of formation in reconstituted whole blood samples comparing spray-dried plasma versus . Vox Sang. 2021 May;116(5):540-546. 34. MacQuarrie KL, Williams O, Friedman KD, Bercovitz RS. Compound heterozygous protein C variants undetectable by common laboratory testing causing after the neonatal period. Am J Hematol. 2020 12;95(12):1616-1621. 35. Colling ME, Friedman KD, Dzik WH. In Vitro Assessment of von Willebrand Factor in , Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619873976. PMCID: PMC6829641 36. van Dorland HA, Taleghani MM, Sakai K, Friedman KD, George JN, Hrachovinova I, Knöbl PN, von Krogh AS, Schneppenheim R, Aebi-Huber I, Bütikofer L, Largiadèr CR, Cermakova Z, Kokame K, Miyata T, Yagi H, Terrell DR, Vesely SK, Matsumoto M, Lämmle B, Fujimura Y, Kremer Hovinga JA, Hereditary TTP Registry. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019 10;104(10):2107-2115. PMCID: PMC6886414 37. Horn C, Négrier C, Kalina U, Seifert W, Friedman KD. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost. 2019 01;17(1):138-148. PMCID: PMC7379984 38. Flood VH, Abshire TC, Christopherson PA, Friedman KD, Cox Gill J, Montgomery RR, Haberichter SL, Zimmerman Program Investigators. Von Willebrand disease in the United States: perspective from the Zimmerman program. Ann Blood. 2018 Jan;3. PMCID: PMC6100783 39. Flood VH, Johnsen JM, Kochelek C, Slobodianuk TL, Christopherson PA, Haberichter SL, Udani R, Bellissimo DB, Friedman KD, Montgomery RR. Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD. Res Pract Thromb Haemost. 2018 Apr;2(2):390-398. PMCID: PMC5974909 40. Friedman KD, Powell JS, Bensen-Kennedy D. Response: The coagulation laboratory monitoring of AFSTYLA single-chain FVIII concentrate. Haemophilia. 2018 05;24(3):e129-e131. 41. St Ledger K, Feussner A, Kalina U, Horn C, Metzner HJ, Bensen-Kennedy D, Blackman N, Veldman A, Stowers A, Friedman KD. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J Thromb Haemost. 2018 03;16(3):555-564. 42. Fattah H, Kumar D, George JN, Massey HD, King AL, Friedman KD, Gupta G. Successful transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Transfusion. 2017 12;57(12):3058-3062. 43. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017 11;57(11):2775-2781. 44. George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. Am J Hematol. 2021 08 01;96(8):E301-E303. 45. Tarasco E, Bütikofer L, Friedman KD, George JN, Hrachovinova I, Knöbl PN, Matsumoto M, von Krogh AS, Aebi-Huber I, Cermakova Z, Górska-Kosicka M, Jalowiec KA, Largiadèr CR, Prohászka Z, Sinkovits G, Windyga J, Lämmle B, Kremer Hovinga JA. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood. 2021 Jun 24;137(25):3563-3575.

6 / 7 46. Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lämmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 04 08;137(14):1855-1861.

Powered by TCPDF (www.tcpdf.org) 7 / 7